DealsOct 20, 2026, 06:06 AM
Clene Inc. Secures $7.2M NIH Grant Amendment for ALS Treatment Program
AI Summary
Clene Inc. announced on October 15, 2026, that it entered into a subaward amendment with New York University (NYU) for the fourth year of a National Institute of Health (NIH) grant. The amendment provides up to $7.2 million for the period of September 1, 2026, to August 31, 2027. This NIH Grant supports an Expanded Access Program for CNM-Au8® treatment of amyotrophic lateral sclerosis. The total obligated funds to date for this subaward now amount to $15,258,081.00.
Key Highlights
- Clene Inc. entered into a subaward amendment for the fourth year of the NIH Grant with NYU for up to $7.2 million.
- The NIH Grant supports an Expanded Access Program for CNM-Au8® treatment of amyotrophic lateral sclerosis.
- The subaward amendment covers the period from September 1, 2026, to August 31, 2027.
- The total amount of funds obligated to date for this subaward is $15,258,081.00.
- The amendment includes additional funding of $7,214,420.00.
Price Impact
More from CLNN